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During the last thirty years the understanding and medical
management of Peripheral Arterial Disease (PAD) has evolved
considerably. Though traditional surgical reconstruction had been
the mainstay treatment for failure of medical or local wound
therapy, the introduction and development of endovascular
procedures has signiﬁcantly expanded the therapeutic options for
treating this patient population. Between 1995 and 2000, catheter-
based interventions for infrainguinal disease had increased by
nearly 1000%.1 In addition, for the ﬁrst time, there has been
a concurrent decrease in the major amputation rates in “at risk
patients”, although one has to be cautious about linking this
outcome improvement to a speciﬁc treatment modality or care
improvement.2
It is sometimes difﬁcult to assess and compare new modalities
of care such as endovascular procedures to traditional bypass
surgery. This is especially true when considering lower extremity
peripheral occlusive disease, where the type of symptomatic
presentation, the corresponding anatomic obstructions, the plaque
composition and systemic patient metabolic abnormalities provide
a wide spectrum of disease and a very heterogeneous population
that makes correlating clinical endpoints between treatment
modalities very challenging. This difﬁculty is further ampliﬁed with
recent, rapid improvements of medical therapy for atherosclerotic
occlusive disease which have had a varied geographic penetration
into this population of patients.
Despite these limitations, some comparisons can be made.
When analyzing periprocedural outcomes of infrainguinal revas-
cularization during the last decade, endovascular treatment has
a signiﬁcantly lower procedural morbidity/mortality, and hospital
length of stay compared to open bypass surgery.3 With ease of
patient tolerance of these procedures, and increased familiarity of
vascular specialist of its capabilities, endovascular therapy is
increasingly considered as the initial treatment of choice for
symptomatic patients with PAD, whether the lesions are simple or
complex, focal or diffuse, single or multiple, calciﬁed or non-* Corresponding author. Tel.: þ1 67 726 6997; fax: þ1 617 724 1921.
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endovascular-ﬁrst approach reduces morbidity, mortality,
and costs while preserving surgical options for subsequent
revascularizations.6e8
Opponents of the use of percutaneous trans-luminal angioplasty
(PTA) as the initial treatment emphasize its inferior long-term
primary patency when compared to vein-graft bypass surgery. To
maintain a comparable mid-term and long-term assisted patency
and limb salvation with PTA, patients frequently require secondary
procedures more often than after bypass surgery. For this reason,
these proponents believe that in young patients with a reasonable
long-term life expectancy, bypass surgery should be the ﬁrst-line
treatment. To argue an endovascular ﬁrst-line strategy even in
patients under 65 years-old, the following arguments will be
proposed:
 Patients with PAD have a signiﬁcantly reduced life expectancy,
making use of an endovascular approach a timely
consideration.
 Periprocedural morbidity and mortality are considerably lower
with PTA.
 Secondary interventions after primary endovascular failure are
safe, effective and provide assisted-patency and limb salvation
comparable to undertaking ﬁrst-line bypass surgery.
 Bypass failure as compared to PTA failure can be an ominous
event for patients with PAD resulting in poor outcome for limb
preservation.
 Costs between PTA and bypass are comparable.
Patients with PAD have a signiﬁcantly reduced life expectancy,
making use of an endovascular approach a timely consideration
Excluding the patients with Critical Limb Ischemia (CLI) that
have evenworse longevity, the 5, 10 and 15 year all-cause mortality
rates for patients with symptomatic PAD are 30%, 50% and 70%
respectively.9 In fact, the mortality rate of the patients with clau-
dication is 2.5 times higher than age-matched controls.9 Patients
with chronic CLI have a 20% mortality in the ﬁrst year after
presentation, and the recent long-term results of the BASIL trial
showed a 56% mortality rate at 4 years,10 while another recented by Elsevier Ltd. All rights reserved.
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death rate.5
Coronary artery disease is by far the most common cause of
death among patients with PAD (40%e60%), with cerebral artery
disease accounting for 10%e20% of deaths.9 There are multiple
predictive factors of mortality in PAD patients which can further
stratify the individual patient’s risk, including: age, presence of
tissue loss, serum creatinine, extent of coronary artery disease and
cerebro-vascular disease, severity of the PAD itself, body mass
index, smoking status, pulmonary disease and congestive heart
failure.7,11,12
Therefore, patients with symptomatic PAD have a signiﬁcantly
shortened longevity compared to the general population. As such,
when considering a treatment for symptomatic infrainguinal
disease, minimizing periprocedural morbidity and rehabilitation
time take on a higher importance while extended durability of the
reconstructions, though always a high priority, need to be consid-
ered relative to the patient’s life expectancy.
Peri-procedural morbidity and mortality are considerably lower
with PTA
There has been good evidence that the more extensive the
vascular procedure, the higher the peri-procedural morbidity and
mortality.13,14 In a large, prospective, contemporary series of 2404
patients (mean age 67years) undergoing infrainguinal bypass
surgery, the 30 day mortality was 2.7% with the composite
mortality/major morbidity rate of 19.5%.13 Major complications
occurred in 18.7%, which encompassed 9.4% of wound infections
and 7.4% graft thromboses. A subanalysis of this data for only
claudication patients (52%), revealed a lower mortality (2%) and
composite major morbidity and mortality (14.5%). Results were
comparable in the prospective, randomized PREVENT III trial (mean
age 68 years), of vein graft bypass in patients with CLI that iden-
tiﬁed a 30-day mortality of 2.7% with major complications of
17.8%.15
With judicious hydration and limiting iodinated contrast
administration, peri-procedure morbidity after PTA is unusual and
mostly due to groin hematoma, bleeding and development of
a pseudoaneurysm.5 Complication rates have been reported as
1e5% in patients with claudication16,17 and 2e5% in the CLI
patients.7 In a recent large study of PTA in CLI patients (mean age 70
years) there was a rate of 4% of groin or retroperitoneal hematoma
requiring transfusion.5
Mean hospital stay after an infra-inguinal PTA is 1day (0.02
days) with an immediate return to active life especially in inter-
mittent claudication patients, while length of stay after surgery is
4.52 0.31 days.18 Examining short term outcomes of infrainguinal
vein bypass, hospital readmissions within 6 months have been
reported in 49% of patients, 65% of which were related to problems
resulting from the index operation.6 As there is lower complication
rate for PTA, the 30 day hospital re-admission rate has been
reported to be 6%.19
Peripheral Arterial Disease and especially CLI causes natural
reduction of physical function. The ultimate goal in these patients is
a functional status and quality of life. At 6 months, a study evalu-
ating diabetics undergoing infrainguinal bypass for limb salvage
reported that less than half of the patients felt being "back to
normal" and 74% of patients required devices to assist with
walking.20 Interestingly, the functional status at follow-up was
independent of patient age in this primarily diabetic cohort of
patients. Another study focusing on functional outcomes after
bypass for CLI identiﬁed a 19% loss of ambulation and a 5% loss of
independent living.21 A recent meta-analysis examined pre- and
post-operative ambulatory status and independent living inpatients undergoing revascularization for CLI. Of the 10 studies that
reviewed bypass outcomes 6e12 months postoperative, there was
a 12% decline in ambulatory status and a 15% loss of semi-
independent living.22 In the meta-analysis there was only one
study that evaluated ambulatory status 12 months after PTA in
a cohort of 122 patients. In that cohort of patients there was a 6%
loss of ambulatory status.22 The BASIL trial also addressed this issue
in their short and long term follow up data with no signiﬁcant
improvement in quality of life between the PTA and bypass
groups.23
In summary, infrainguinal treatment for symptomatic PAD with
PTA offers a lower rate of peri-operative morbidity and mortality
than Bypass for both patients with claudication and CLI, resulting in
a faster return to normal daily activity.
Secondary interventions after primary endovascular failure are safe,
effective and provide assisted-patency and limb salvation
comparable to undertaking ﬁrst-line bypass surgery
Results of the BASIL randomized study conﬁrmed that endo-
vascular and vein-graft bypass treatment of CLI have a similar
amputation-free survival and assisted clinical success rates at 2
years.6 Comparison between 2 meta-analyses of infrageniculate
reconstruction for CLI: popliteal-to-distal vein bypass grafts24 and
infrapopliteal angioplasty25 provided similar outcomes. Both
studies used similar methods and targeted the same patient
population. At one month, six months, 1 year, 2 years, and 3 years,
primary patency were higher with bypass reconstruction.
However, overall limb salvage was comparable in both meta-
analyses (82%).24,25
Using PTA to treat the femoral-popliteal segment also provides
very respectable outcomes with primary and assisted patency at 3
years of 65% and 93% respectively.17 Infra-popliteal PTA with 40
months average follow up identiﬁed a primary patency of 62%, an
assisted patency of 90% and an overall limb preservation rate of
86%.7 More recently, an evaluation of 409 CLI patients treated with
PTA as a ﬁrst-line therapy demonstrated at 5 years, a low primary
patency (31%), an assisted patency that improved to 75%, and an
excellent limb salvage rate (74%).5
The BASIL study is the only randomized study to try to answer
the question of superiority of bypass surgery-ﬁrst vs PTA-ﬁrst in
treatment of CLI patients.6 The 5 year results do indicate that in the
analysis of only the subgroup of patients who have survived 2 years
after randomization (subset of survivors, not all patients), therewas
a signiﬁcantly higher overall survival in the bypass-ﬁrst group but
not a signiﬁcant higher amputationefree survival, even suggesting
they may be different patient cohorts.26 There was also a higher
early failure rate of PTA-ﬁrst patients compared to surgery-ﬁrst
patients, and that many of the PTA-ﬁrst patients ultimately
required bypass surgery. Another conclusion was that surgical
patients who had undergone prior PTA had worse outcomes than
those who only had surgery.10 However, this did not address the
speciﬁc question of whether a prior PTA later excluded, by loss of
anatomic runoff, a subsequent surgical option, but rather that
patient who had surgery after failed PTA did not fare as well as
those that had only a primary surgery. Indeed, as this is a group of
a failed intervention, they may have been more appropriately
compared to the group of surgery after a failed surgical procedure.
Although the BASIL trial is level 1 evidence data, there are
several problems with it that would indicate some caution in the
data interpretation. The investigational site audits, including the
suitability of randomization, consent, and crossover to the opposite
arm of the study resulted in approximately 1 in 10 presenting
patients actually enrolling in the study arm that they were origi-
nally randomized to, thus somewhat pre-selecting the cohort of
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study was undertaken primarily by radiologists and the surgery
arm by the surgeons, which may introduce differences in the
approach and the treatment of these complex patients with
multilevel disease.10
A large prospective registry-based study on infrapopliteal
procedures in CLI highlighted that bypass and surgery achieved
similar 5-year leg salvage (75.3% vs 76.0%), survival (47.5% vs 43.3%),
and amputation free survival (37.7% vs 37.3%) rates.27 To reduce
confounding factors, a propensity score was used to analyze the
data which yielded equivalent results of both PTA-ﬁrst and bypass-
ﬁrst treatment arms.
PTA of the superﬁcial femoral artery has better primary, assisted
primary and secondary patency than prosthetic bypass in the above
knee position.28 Femoro-distal bypass with a prosthetic graft have
a very low secondary patency (25% at 5 years) and are known to
have loss of outﬂow during graft failure.29 Therefore, in patients
with no available venous conduit, or are at a high risk for bypass,
PTA can be considered the preferred initial therapy for TASC B and C
lesions.30
In summary, infra-inguinal vein bypass have the highest
primary patency rates long-term. However, through close follow-
up and secondary interventions similar limb salvation rates can
be achieved with PTA treatment. Mid-term and long-term patency
is better with PTA when compared to prosthetic bypass.Bypass failure as compared to PTA failure can be an ominous event
for patients with PAD resulting in poor outcome for limb
preservation
When performed by an experienced interventionist who
understands the limits of the technique and the subsequent
surgical options for revascularization, an attempted or failed PTA
for infra-inguinal arterial disease can very often be safely treated
either by a new PTA or surgical bypass. Multiple studies have
demonstrated that ﬁrst-line therapy with PTA/stent does not
preclude re-intervention with PTA or secondary surgical revascu-
larization.17,31,32 All studies showed that secondary bypass feasi-
bilities, patency and limb salvation rates were similar to the
primary bypass patency and feasibilities.33,34 The contradiction of
these observations in the BASIL study10 has been addressed in the
previous section. Another study raised the question of a prior PTA
resulting in a lower success rate of subsequent bypass.35 There
were several limitations in this study. The data were obtained from
a database where the anatomic site and the number of PTA prior to
bypass were unknown. In addition the group with a prior PTA was
mostly female and required the use of arm vein conduit, two factors
associated with inferior long term patency.
Consequences of a failed infra-inguinal bypass can be more
deleterious.36 Early graft failure (within 1 month of surgery) has
been reported in approximately 5%e10% of cases37,38 and has been
correlated with increased limb loss.37 In addition, the long-term
secondary patency of a thrombosed vein graft that has undergone
thrombectomy or thrombolysis is around 36% at 1 year.39 Re-
operative bypass surgery for a failed graft also has inferior results.
Results of those secondary bypass surgeries are also poor (14% early
graft failure with vein graft and 30% with prosthetic grafts, 50%
primary patency at 5 years with venous bypass), which is mainly
due to severe scarring in the operative ﬁeld or lack of ipsilateral
saphenous vein necessitating use of alternative poor vein conduits
or prosthetic grafts.40,41
The percutaneous procedure should be always undertaken with
consideration of backup surgical options should the initial PTA be
unsuccessful or fail. Thrombosis of a bypass is a poor prognosticfactor as secondary patency is poor and secondary bypasses have
diminished long term patency.
Costs between PTA and bypass are comparable
In the BASIL trial, the peri-procedural morbidity of PTA-ﬁrst was
signiﬁcantly lower than bypass-ﬁrst line strategy. As a conse-
quence, the resource utilization and hospital length of stay were
signiﬁcantly higher in the surgery group. This was responsible for
a mean hospital cost one third higher in the bypass group during
the ﬁrst year.6,42 Owing to a higher rate of re-intervention over the
duration of the study in the PTA-ﬁrst cohort, the cost between the 2
groups equalized by the end of the study.23 Cost analysis is also
dependant on practice patterns, use of stents, and differences in
patient’s clinical presentation. In addition, the equipment expen-
diture between 2001 and 2007 has seen the average cost for PTA
increased over 60% for claudication and limb threatening ischemia,
reaching $14,084 and $23,196 respectively.18 From, recent data
comparing PTA and surgery treatment in appropriately selected
patients, the amortized cost per day of patency is comparable in
both claudication or chronic limb ischemia patients.8
Conclusion
Although treatment of risk factors for PAD has made signiﬁcant
advances in the last several decades, failure of medical therapy
resulting in symptomatic infrainguinal occlusive disease relies on
either PTA or bypass to improve perfusion. As patients with PAD
have a shorter life expectancy than the general population, themost
effective method of revascularization to get the patients back to
their functional statewould be ideal. Thiswould entail symptomatic
relief, with minimal morbidity and lesion healing, if present, as
the critical end-points. In addition to minimal peri-procedural
morbidity, PTA has a better limb salvage rate and assisted patency
than prosthetic bypass and results that approach the gold standard
of venous bypass. Nevertheless, as bypass surgery may become
a future treatment modality, care should be taken not to undertake
PTAoptions thatmayobviate those possible future treatments. Even
as the present algorithms of medical, interventional and surgical
care for claudication and limb threatening ischemia remain highly
controversial, they have resulted in a 25%decrease the major lower
extremity amputation rate within the last 15 years.2
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